{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:13:02Z","timestamp":1785413582193,"version":"3.56.0"},"posted":{"date-parts":[[2025,11,1]]},"group-title":"Molecular Biology","reference-count":73,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"name":"NIH","award":["R01CA53840"],"award-info":[{"award-number":["R01CA53840"]}]},{"name":"Cancer Center at Cold Spring Harbor Laboratory","award":["CA45508"],"award-info":[{"award-number":["CA45508"]}]},{"id":[{"id":"https:\/\/ror.org\/022cmsc90","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022504","name":"Hansen Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100022504","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  CDKL5-deficiency disorder or CDD, which results in intellectual disability, speech and motor deficits, and seizures that can start as early as six weeks after birth, is caused by de novo mutations in the\n                  <jats:italic>CDKL5<\/jats:italic>\n                  gene. In early 2022, the FDA approved Ganaxolone (Commercial name: Ztalmy) for treatment of seizures in CDD patients 2 years and older. Ganaxolone has been reported to act as a GABAA receptor agonist that helps reduce neuronal excitability; however, based on its chemical structure we hypothesized that ganaxolone may also act as a PTP1B inhibitor. We observed that ganaxalone was able to inhibit PTP1B activity both in an in vitro assay of enzyme activity and in different cell models, in a comparable way to known inhibitors of PTP1B, including MSI-1436, which has a similar chemical structure. Additionally, inhibition of PTP1B in differentiating SH-SY5Y cells increased TRKB\/BDNF signaling. This effect was prominent in CDKL5-KO cells, where inhibition of PTP1B brought TRKB levels and BDNF signaling to levels similar to those of wild-type cells and the observed signaling changes also coincided with restoration of cellular morphology. Finally, loss of CDKL5 function resulted in increased levels of PTP1B. Our results suggest that, like in Rett syndrome, targeting PTP1B may be a beneficial therapeutic strategy for CDD.\n                <\/jats:p>","DOI":"10.1101\/2025.10.31.685887","type":"posted-content","created":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T06:15:16Z","timestamp":1762064116000},"source":"Crossref","is-referenced-by-count":0,"title":["Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B"],"prefix":"10.64898","author":[{"given":"Imanol","family":"Zubiete-Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas K","family":"Tonks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025111413001069000_2025.10.31.685887v2.1","doi-asserted-by":"publisher","DOI":"10.1177\/15353702231209419"},{"key":"2025111413001069000_2025.10.31.685887v2.2","doi-asserted-by":"publisher","DOI":"10.1038\/13810"},{"key":"2025111413001069000_2025.10.31.685887v2.3","doi-asserted-by":"publisher","DOI":"10.1086\/426460"},{"key":"2025111413001069000_2025.10.31.685887v2.4","doi-asserted-by":"publisher","DOI":"10.1086\/426462"},{"key":"2025111413001069000_2025.10.31.685887v2.5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174176"},{"key":"2025111413001069000_2025.10.31.685887v2.6","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2023.1172805\/BIBTEX"},{"key":"2025111413001069000_2025.10.31.685887v2.7","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3390\/ijms23020954","article-title":"Paving Therapeutic Avenues for FOXG1 Syndrome: Untangling Genotypes and Phenotypes from a Molecular Perspective","volume":"23","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025111413001069000_2025.10.31.685887v2.8","doi-asserted-by":"crossref","unstructured":"Medici, G. , Tassinari, M. , Galvani, G. , Bastianini, S. , Gennaccaro, L. , Loi, M. , Mottolese, N. , Alvente, S. , Berteotti, C. , Sagona, G. , Lupori, L. , Candini, G. , Baggett, H. R. , Zoccoli, G. , Giustetto, M. , Muotri, A. , Pizzorusso, T. , Nakai, H. , Trazzi, S. , and Ciani, E . (2022) Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency Disorder. Neurotherapeutics. 19, 1886\u20131904","DOI":"10.1007\/s13311-022-01295-8"},{"key":"2025111413001069000_2025.10.31.685887v2.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00727"},{"key":"2025111413001069000_2025.10.31.685887v2.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41439-024-00296-7"},{"key":"2025111413001069000_2025.10.31.685887v2.11","doi-asserted-by":"publisher","DOI":"10.1086\/444549"},{"key":"2025111413001069000_2025.10.31.685887v2.12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146626"},{"key":"2025111413001069000_2025.10.31.685887v2.13","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.825063"},{"key":"2025111413001069000_2025.10.31.685887v2.14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80323"},{"key":"2025111413001069000_2025.10.31.685887v2.15","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2016.36"},{"key":"2025111413001069000_2025.10.31.685887v2.16","doi-asserted-by":"crossref","first-page":"113709","DOI":"10.1016\/j.biopha.2022.113709","article-title":"Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders","volume":"155","year":"2022","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2025111413001069000_2025.10.31.685887v2.17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.603621"},{"key":"2025111413001069000_2025.10.31.685887v2.18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.24.1.677"},{"key":"2025111413001069000_2025.10.31.685887v2.19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1474-4422(22)00035-7","article-title":"CDKL5 deficiency disorder: clinical features, diagnosis, and management","volume":"21","year":"2022","journal-title":"The Lancet Neurology"},{"key":"2025111413001069000_2025.10.31.685887v2.20","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.3390\/ijms20205098","article-title":"Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic","volume":"20","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025111413001069000_2025.10.31.685887v2.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2025.08.002"},{"key":"2025111413001069000_2025.10.31.685887v2.22","doi-asserted-by":"publisher","DOI":"10.3390\/pediatric16010002"},{"key":"2025111413001069000_2025.10.31.685887v2.23","unstructured":"ZTALMY\u00ae (ganaxolone) CV Official Site | Home [online] https:\/\/www.ztalmy.com\/ (Accessed October 15, 2025)"},{"key":"2025111413001069000_2025.10.31.685887v2.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2025.107669"},{"key":"2025111413001069000_2025.10.31.685887v2.25","doi-asserted-by":"publisher","DOI":"10.15190\/d.2025.7"},{"key":"2025111413001069000_2025.10.31.685887v2.26","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-024-00670-6"},{"key":"2025111413001069000_2025.10.31.685887v2.27","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17826"},{"key":"2025111413001069000_2025.10.31.685887v2.28","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0022-3565(24)36511-5","article-title":"Characterization of the Anticonvulsant Properties of Ganaxolone (CCD 1042; 3\u03b1-Hydroxy-3\u03b2-methyl-5\u03b1-pregnan-20-one), a Selective, High-Affinity, Steroid Modulator of the \u03b3-Aminobutyric AcidA Receptor","volume":"280","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"2025111413001069000_2025.10.31.685887v2.29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fendo.2020.00417","article-title":"Anti-apoptotic Actions of Allopregnanolone and Ganaxolone Mediated Through Membrane Progesterone Receptors (PAQRs) in Neuronal Cells","volume":"11","year":"2020","journal-title":"Front Endocrinol (Lausanne"},{"key":"2025111413001069000_2025.10.31.685887v2.30","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1528"},{"key":"2025111413001069000_2025.10.31.685887v2.31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C117.819110"},{"key":"2025111413001069000_2025.10.31.685887v2.32","doi-asserted-by":"publisher","DOI":"10.3791\/53193"},{"key":"2025111413001069000_2025.10.31.685887v2.33","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi391"},{"key":"2025111413001069000_2025.10.31.685887v2.34","doi-asserted-by":"publisher","DOI":"10.1042\/BST20220791"},{"key":"2025111413001069000_2025.10.31.685887v2.35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.31083\/j.jin2201020","article-title":"SH-SY5Y Cell Line In Vitro Models for Parkinson Disease Research-Old Practice for New Trends","volume":"22","year":"2023","journal-title":"J Integr Neurosci"},{"key":"2025111413001069000_2025.10.31.685887v2.36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.celrep.2017.12.083","article-title":"CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary Function","volume":"22","year":"2018","journal-title":"Cell Reports"},{"key":"2025111413001069000_2025.10.31.685887v2.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2014.06.006"},{"key":"2025111413001069000_2025.10.31.685887v2.38","doi-asserted-by":"publisher","DOI":"10.1086\/375538"},{"key":"2025111413001069000_2025.10.31.685887v2.39","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2012.156"},{"key":"2025111413001069000_2025.10.31.685887v2.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.02.015"},{"key":"2025111413001069000_2025.10.31.685887v2.41","doi-asserted-by":"crossref","first-page":"e143655","DOI":"10.1172\/JCI143655","article-title":"Temporal manipulation of Cdkl5 reveals essential postdevelopmental functions and reversible CDKL5 deficiency disorder-related deficits","volume":"131","year":"2021","journal-title":"J Clin Invest"},{"key":"2025111413001069000_2025.10.31.685887v2.42","doi-asserted-by":"publisher","DOI":"10.1352\/1944-7558-129.2.101"},{"key":"2025111413001069000_2025.10.31.685887v2.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110504"},{"key":"2025111413001069000_2025.10.31.685887v2.44","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.3390\/ijms20205098","article-title":"Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic","volume":"20","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025111413001069000_2025.10.31.685887v2.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.012"},{"key":"2025111413001069000_2025.10.31.685887v2.46","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-021-09384-z"},{"key":"2025111413001069000_2025.10.31.685887v2.47","doi-asserted-by":"publisher","DOI":"10.1080\/01926230701226575"},{"key":"2025111413001069000_2025.10.31.685887v2.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00170-4"},{"key":"2025111413001069000_2025.10.31.685887v2.49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","year":"2022","journal-title":"The Lancet Neurology"},{"key":"2025111413001069000_2025.10.31.685887v2.50","doi-asserted-by":"publisher","DOI":"10.1177\/15357597221125238"},{"key":"2025111413001069000_2025.10.31.685887v2.51","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2342413"},{"key":"2025111413001069000_2025.10.31.685887v2.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2024.06.005"},{"key":"2025111413001069000_2025.10.31.685887v2.53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091613"},{"key":"2025111413001069000_2025.10.31.685887v2.54","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddx279"},{"key":"2025111413001069000_2025.10.31.685887v2.55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196587"},{"key":"2025111413001069000_2025.10.31.685887v2.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10689-w"},{"key":"2025111413001069000_2025.10.31.685887v2.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106146"},{"key":"2025111413001069000_2025.10.31.685887v2.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113388"},{"key":"2025111413001069000_2025.10.31.685887v2.59","doi-asserted-by":"crossref","first-page":"105176","DOI":"10.1016\/j.nbd.2020.105176","article-title":"X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder","volume":"148","year":"2021","journal-title":"Neurobiol Dis"},{"key":"2025111413001069000_2025.10.31.685887v2.60","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.09.983981"},{"key":"2025111413001069000_2025.10.31.685887v2.61","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-025-00882-9"},{"key":"2025111413001069000_2025.10.31.685887v2.62","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2716"},{"key":"2025111413001069000_2025.10.31.685887v2.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.08.028"},{"key":"2025111413001069000_2025.10.31.685887v2.64","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.482737"},{"key":"2025111413001069000_2025.10.31.685887v2.65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fncel.2019.00169","article-title":"Functional and Structural Impairments in the Perirhinal Cortex of a Mouse Model of CDKL5 Deficiency Disorder Are Rescued by a TrkB Agonist","volume":"13","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"2025111413001069000_2025.10.31.685887v2.66","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02204-0"},{"key":"2025111413001069000_2025.10.31.685887v2.67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158719"},{"key":"2025111413001069000_2025.10.31.685887v2.68","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0545-3"},{"key":"2025111413001069000_2025.10.31.685887v2.69","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.30.657101"},{"key":"2025111413001069000_2025.10.31.685887v2.70","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.592514"},{"key":"2025111413001069000_2025.10.31.685887v2.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.02.028"},{"key":"2025111413001069000_2025.10.31.685887v2.72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00136"},{"key":"2025111413001069000_2025.10.31.685887v2.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2024.02.008"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.31.685887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:16:00Z","timestamp":1782278160000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.10.31.685887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":73,"URL":"https:\/\/doi.org\/10.1101\/2025.10.31.685887","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.jbc.2026.113178","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,11,1]]},"subtype":"preprint"}}